Insider buying last 90 days
No open-market insider purchases were filed for SYK in the last 90 days.
From Form 4 filings, dated to when each was filed.
Every SYK insider filing, plotted on the chart in Gekko.Open SYK in Gekko
NYSE: SYK
Stryker (SYK) Stock Analysis & Forecast
Nov 4 close
$339.65+29.10 (+9.4%)
Gekko Brief
AI summaryNov 4 closeStryker shares surged this week after election results showed Democrats reclaiming majorities in Congress, lifting shares alongside peers Omnicell, Zimmer Biomet, Artivion, and Dentsply Sirona. Separately, Stryker disclosed a US$400 million investment in UK surgical robotics developer CMR Surgical, with an exclusive option to acquire the remaining equity. Rothschild & Co Redburn trimmed its price target to $336.00 from $360.00, while commentary continued around the Orthopaedics division's slower hip and knee growth, which had prompted a lowered 2026 organic sales growth forecast following last week's Q3 report. Stryker also filed a mixed shelf registration covering a range of securities.
Stryker closed at $339.65, up 9.4%, with the stock sitting above both its 50-day average of $292.09 and 200-day average of $323.18. The one-month return stands at 22.1%, though the one-year return remains negative at -5.2%. The GekkoIndex reads 43.1, placing the stock in the Distribution zone, down 9.1 over five sessions. Price sits 6.5% above the Gekko Fair Value of $318.89.
The next earnings date falls on 4 February 2027, 91 days out, beyond a typical 20-trading-day holding window. Over the last 90 days, Congressional activity shows 1 buy and 0 sells. Options traders have shown interest in the Dec 18, 2026 $560 Put, pointing to elevated implied volatility over the last 30 days. Seasonally, the next 20 trading days have averaged a 3.4% return across 5 years, with gains in 4 of them, a pattern worth noting alongside the current Distribution reading.
Written by AI from the Nov 4, 2026 close and checked automatically against the figures on this page.
Stryker price vs fair value
Close $339.65200-day averageGekko Fair Value $318.89
Stryker quick facts
- Market cap
- $130.3B
- P/E ratio
- 32.7
- Forward P/E
- 17.5
- EPS, TTM
- $9.39
- Revenue, TTM
- $26.30B
- Profit margin
- 13.8%
- Dividend yield
- 1.21%
- Beta
- 0.77
- Volume
- 6.34M avg 2.95M
- 1-year return
- −5.2%
- Typical daily move
- ±3.5%
- Typical 20-day move
- ±4.4%
- 50-day average
- $292.09
- 200-day average
- $323.18
- Next earnings
- Feb 4 after close
- Shares outstanding
- 380.7M
Stryker swing-trade checklist
Stryker scores 3 supportive, 1 mixed and 2 headwinds across the 6 checklist items with data.
Six things swing traders check before a 20-day hold, read from the latest data.
3 supportive1 mixed2 headwinds
- Trendmixed
Averages disagree
Close $339.65 sits between the 50-day ($292.09) and 200-day ($323.18) averages, or the averages disagree.
See the chart - GekkoIndexheadwind
43.1, Distribution
Reading 43.1 is in the Distribution zone.
See the GekkoIndex - Fair valueheadwind
6.5% above
Price is 6.5% above Gekko Fair Value (more than 5% above).
See fair value - Smart moneysupportive
Leans bullish
Last 90 days: Congress 1 buy / 0 sales.
See smart money - Earnings risksupportive
Reports in 91 days
Next report Feb 4, 2027, 91 days away — outside a typical 20-trading-day hold.
See earnings - Seasonalitysupportive
+3.4% on average
From this point in the calendar, the next 20 trading days averaged +3.4% over 5 years, rising in 4 of them.
See seasonality
A description of current data, not a recommendation. How this page works
Stryker stock chart and price history
Stryker closed at $339.65 on Nov 4, 2026, −5.2% over the past year, inside a 52-week range of $267.00 to $389.33.
Close50-day average200-day averageVolume
Use the left and right arrow keys to read daily values.
Performance Breakdown
- 1 month
- +22.1%
- 3 months
- +0.7%
- 6 months
- +16.2%
- 1 year
- −5.2%
The full SYK chart adds GekkoIndex, insider, options, Congress and hedge fund markers, plus TrendCandles™.Open SYK in Gekko
Follow Stryker through every session
Put SYK on a Gekko watchlist and see its GekkoIndex, Gekko Fair Value and smart money signals update on the chart as they change.
Track SYK in GekkoFree for 7 days. No credit card required.
About Stryker
Stryker makes medical technology used in surgery and patient care, with much of its recognition tied to joint replacement implants for hips and knees as well as spinal hardware used in treating injuries, deformities and degenerative conditions of the spine.
The company organizes its work into two broad areas. One centers on orthopaedic implants and trauma and extremities repair, along with spinal systems covering cervical, thoracolumbar and interbody needs. The other spans surgical equipment, navigation systems, endoscopy and communication tools, patient handling and emergency care devices, and disposable items used in critical care, plus reprocessed and remanufactured devices. Within this second area, Stryker also supplies neurotechnology products, including tools for endovascular procedures, brain and skull-base surgery, synthetic bone grafts, vertebral augmentation, stroke treatment devices, craniomaxillofacial implants, and dural substitutes and sealants. Its customers are doctors, hospitals and other healthcare providers, reached through its own subsidiaries, regional offices, and outside dealers and distributors across roughly 75 countries.
Stryker was founded in 1941 and is headquartered in Kalamazoo, Michigan. Its shares are listed on the NYSE under the ticker SYK.
- Listed
- NYSE
- Sector
- Health technology
- Industry
- Medical specialties
- Website
- stryker.com
Stryker GekkoIndex: the smart money zone
Stryker’s GekkoIndex — Gekko’s 0 to 100 smart money score — reads 43.1, in the Distribution zone, down 9.1 points over five sessions.
43.1Distribution
Down 9.1 points over five sessions, from the Neutral zone.
Reading for Nov 4, 2026
What followed past readings in each zone
| Zone | Readings | 5 days | 20 days | ||
|---|---|---|---|---|---|
| Buying | 38 | +1.3% | +3.4% | ||
| Accumulation | 252 | +0.3% | +1.9% | ||
| Neutral | 378 | −0.3% | −1.8% | ||
| Distribution (current zone) | 28 | +0.3% | +0.4% | ||
| Selling | 1 | Too few readings yet | |||
Average SYK share-price change over the trading days after each daily reading in its GekkoIndex history. Across every stock Gekko tracks, Distribution readings averaged +1.2% over 20 days. Past behaviour doesn’t guarantee future results.
Distribution zone: Institutions potentially offloading. About the five zones →
See every daily GekkoIndex reading plotted over the SYK price, zone by zone.Track SYK in Gekko
Is Stryker stock overvalued? Gekko Fair Value
Stryker trades 6.5% above Gekko Fair Value of $318.89, so the shares are overvalued on Gekko’s estimate.
Gekko’s own estimate of what Stryker shares are worth, recalculated every trading day.
$318.89
Gekko Fair Value, Nov 4, 2026
6.5% Overvalued
At the end of Aug 2026 the price was 5.9% below the estimate.
Gekko Fair ValueShare price, month end
Gekko Fair Value on every chart, with the gap to price updating daily.Open SYK in Gekko
Stryker insider and Congress trading
No open-market insider purchases were filed for Stryker, and members of Congress disclosed 1 purchase and 0 sales, in the last 90 days.
Plus buybacks, unusual options and fund positions, each dated to when it became public.
Congress trades last 90 days
1trade disclosed: 1 purchase and 0 sales.
| Member | Amount | Disclosed |
|---|---|---|
| Ro Khanna House, CA, purchase | $1,001 - $15,000 | Oct 9 traded Sep 4 |
From congressional disclosures, which report amounts as ranges.
Buybacks
Stryker has been buying back its own shares.
- Bought back, quarter ended Sep 30, 2026
- $1.00B
- As a share of market cap
- 0.77%
From company filings.
Hedge funds and billionaires quarter ended Jun 30
2of the funds Gekko tracks hold SYK.
1added0opened1trimmed0sold out
Which funds are on each side, name by name.Unlock in Gekko
Stryker earnings: next date and track record
Stryker reports on Feb 4, 2027, after the close (91 days away), and beat the EPS estimate in 6 of its last 8 reports.
Next earnings report
Feb 4, 2027
Expected after the close, 91 days away
- EPS estimate
- $5.03
- Revenue estimate
- $7.71B
6 of 8reports beat the EPS estimate
±4.2%average move across the report
2 of 8reports followed by a gain
Share-price move across each report
Last earnings call, Oct 29, 2026 AI summary
- What they said
- Stryker reported Q3 2026 organic sales growth of 7.7%, with MedSurg/Neurotechnology up 9.1% and Orthopaedics up 5.9%. Results fell short of expectations due to Hip/Knee market slowdown driven by affordability concerns, insurance pre-authorization denials, and soft European markets. A Q1 cyber incident and July SAP implementation disrupted commercial execution. Peripheral Vascular showed sequential improvement with a one-time China JV revenue milestone partially offsetting supply disruption impacts.
- Guidance
- Q4 organic growth expected at similar rate to Q3's 7.7%. Management noted continued strong capital demand with elevated order book. Margin expansion efforts are limiting EPS impact from sales shortfall, with strong cash flow generation continuing.
| Reported | EPS | Revenue | Move |
|---|---|---|---|
| Oct 29, 2026 | $3.52 est $3.55 | $6.52B est $6.62B | −4.0% |
| Jul 30, 2026 | $3.69 est $3.46 | $6.59B est $6.58B | −7.5% |
| Apr 30, 2026 | $2.60 est $2.98 | $6.02B est $6.34B | −6.5% |
| Jan 29, 2026 | $4.47 est $4.40 | $7.17B est $7.12B | +3.3% |
| Oct 30, 2025 | $3.19 est $3.13 | $6.06B est $6.04B | −3.6% |
| Jul 31, 2025 | $3.13 est $3.07 | $6.02B est $5.94B | −5.6% |
| May 1, 2025 | $2.84 est $2.71 | $5.87B est $5.69B | +1.1% |
| Jan 28, 2025 | $4.01 est $3.87 | $6.44B est $6.36B | −2.2% |
“Move” is the close of the first session after the report compared with the close of the last session before it, so it reads the same whether the company reported before the open or after the close.
Stryker stock forecast and analyst price targets
Analysts’ average 12-month price target for Stryker is $341.37, +0.5% from the last close, from 21 firms rating the stock in the last 90 days.
$341.37consensus 12-month target, +0.5% from the last close
Now $339.65Avg $341.37
Low $290High $405
Each firm’s latest rating in the last 90 days: 21 firms.
Latest analyst actions
| Date | Firm | Target | vs price |
|---|---|---|---|
| Nov 2 | Citi | $315 | −7.3% |
| Nov 2 | Stifel Nicolaus | $325 | −4.3% |
| Nov 2 | Leerink Partners | $340 | +0.1% |
| Nov 2 | Canaccord Genuity | $300 | −11.7% |
| Nov 2 | Truist Financial | $305 | −10.2% |
+0.4%average 20-day move after past Distribution readings
+3.4%average move over the next 20 trading days in the last 5 years
±3.5%typical daily move, from the 14-day average range
Gekko doesn’t publish price predictions. These are analyst targets and historical base rates, which don’t guarantee future results.
Stryker seasonality: the next 20 trading days
Over the next 20 trading days from Nov 4, Stryker averaged +3.4% across the last 5 years, rising in 4 of them.
Next 20 trading days, by year
Average move and hit rate
| Window | Average | Years higher |
|---|---|---|
| Next 5 trading days | +1.3% | 3 of 5 |
| Next 10 trading days | +2.4% | 3 of 5 |
| Next 15 trading days | +2.5% | 4 of 5 |
| Next 20 trading days | +3.4% | 4 of 5 |
| Next 30 trading days | +2.0% | 3 of 5 |
For scale, SYK’s typical 20-trading-day move in either direction is about 4.4%.
Stryker market cap and key statistics
Stryker’s market cap is $130.3B, with a P/E ratio of 32.7 and revenue of $26.30B over the last twelve months.
Valuation
- Market cap
- $130.3B
- P/E ratio
- 32.7
- Forward P/E
- 17.5
- EPS, TTM
- $9.39
- Gekko Fair Value
- $318.89
Trading
- Volume
- 6.34M
- Avg volume, 20 days
- 2.95M
- 52-week high
- $389.33
- 52-week low
- $267.00
- Shares outstanding
- 380.7M
Financials
- Revenue, TTM
- $26.30B
- Profit margin
- 13.8%
- Return on equity
- 16%
- Quarterly earnings growth, YoY
- −11.7%
Risk and income
- Beta
- 0.77
- Typical daily move
- ±3.5%
- Typical 20-day move
- ±4.4%
- Dividend yield
- 1.21%
Stryker stock news this week
Coverage of Stryker this week reads negative: 2 positive, 7 neutral and 14 negative headlines.
- Stryker (SYK) files mixed shelfStreetInsider, Nov 4
- Stock, debt and warrants may be offered by Stryker (SYK), with terms set for each offering.Stock Titan, Nov 4
- Stryker, Omnicell, Zimmer Biomet, Artivion, and Dentsply Sirona shares are soaring, what you need to knowStockStory, Nov 4
- Stryker (NYSE:SYK) Price Target Cut to $336.00 by Analysts at Rothschild & Co RedburnMarketBeat, Nov 4
- Are Options Traders Betting on a Big Move in Stryker Stock?TradingView, Nov 4
- 15,025 Shares of Stryker Corporation $SYK Purchased by First Nebraska Trust CoMarketBeat, Nov 4
Stryker peers
Stryker’s 6 largest industry peers by market value, with today’s move, GekkoIndex zone and gap to Gekko Fair Value.
| Stock | GekkoIndex zone | vs Fair Value |
|---|---|---|
| TMOThermo Fisher Scientific | Neutral | 14.5% above |
| ABTAbbott Laboratories | Distribution | 8.0% below |
| ISRGIntuitive Surgical | Distribution | 30.4% above |
| DHRDanaher | Neutral | 3.6% above |
| MDTMedtronic | Neutral | 16.0% below |
| BSXBoston Scientific | Neutral | 26.8% below |
A peer links to its own page where one exists.
Stryker stock FAQ
What is Stryker’s market cap?
Stryker’s market cap is $130.3B at the Nov 4, 2026 close of $339.65, with 380.7M shares outstanding. The shares trade on a P/E ratio of 32.7.
What is the Stryker stock forecast?
The consensus analyst 12-month price target for Stryker is $341.37, +0.5% from the last close. Of the 21 firms that rated the stock in the last 90 days, 18 rate it a buy, 3 a hold and 0 a sell. Gekko doesn’t publish price predictions of its own.
Is Stryker stock overvalued or undervalued?
On Gekko’s estimate Stryker is overvalued: the Nov 4, 2026 close of $339.65 is 6.5% above Gekko Fair Value of $318.89. Gekko Fair Value is recalculated every trading day, and a gap inside 5% either way counts as about fair value.
When does Stryker report earnings next?
Stryker is expected to report on Feb 4, 2027, after the market closes (91 days away). Analysts expect earnings of $5.03 per share on revenue of $7.71B. Stryker beat the earnings estimate in 6 of its last 8 reports, moving 4.2% on average across the report.
What is Stryker’s 52-week high and low?
Stryker’s 52-week high is $389.33 and its 52-week low is $267.00; it closed at $339.65 on Nov 4, 2026, −5.2% over the past year. Over the last five years the shares peaked at $406.19 on Jan 28, 2025.
Is Stryker stock a buy right now?
Gekko describes the data; it does not make buy or sell recommendations. On the swing-trade checklist, 3 of the 6 items with data read as supportive (smart money, earnings risk and seasonality), 1 as mixed (trend) and 2 as headwinds (gekkoindex and fair value). The checklist is a description of current data, not a recommendation.
How this page works
During US trading hours the price at the top of the page is a delayed quote, refreshed every 15 minutes; everything else is rebuilt after each US market close. The GekkoIndex, Gekko Fair Value and the checklist are Gekko’s own, and the Gekko Brief is written by AI from this page’s data and checked against it before it is published. How Gekko’s data works →
See Stryker the way Gekko members do
Every GekkoIndex reading, insider trade, options bet and Congress disclosure plotted on the chart, plus the 5,800-name screener and trade planning tools.
Join 1,461 other traders using Gekko
Start Your FREE 7 Day Trial → Every feature unlocked. No credit card required.